In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

rEVO Biologics Inc.

Division of LFB SA
www.revobiologics.com

Latest From rEVO Biologics Inc.

Deals Shaping The Medical Industry, September 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June-August 2014.

BioPharmaceutical Medical Device

Heiden seeks: The new AMAG CEO outlines a strategy of cost-reduction and acquisition

William Heiden joined AMAG Pharmaceuticals as president and CEO in May 2012, at a time when the public company was struggling to find its way forward. Since then he's been paving a path toward profitability.

Cardiovascular Cancer

Heiden hired as AMAG CEO

AMAG Pharmaceuticals has enlisted William Heiden as president and CEO and a member of the board of directors. Frank Thomas, who has served as interim CEO of the company since November 2011, will return to his role of executive vice-president and COO. Mr Heiden is the former president and CEO of GTC Biotherapeutics, where he will continue to serve as chair.

Deals Shaping The Medical Industry, April 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
    • Transgenics
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Respiratory, Pulmonary
  • Alias(es)
  • GTC Biotherapeutics Inc.
  • Genzyme Transgenics Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • LFB SA
  • Senior Management
  • Harry M Meade, PhD, SVP, R&D
    Yann Echelard, PhD, Pres.
  • Contact Info
  • rEVO Biologics Inc.
    Phone: (508) 620-9700
    175 Crossing Blvd.
    4th Fl.
    Framingham, MA 01702
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register